Investor Presentation

Date: November 05, 2026 BSE Limited(“BSE”) National Stock Exchange of India Ltd(“NSE”) Phiroze Jeejeebhoy Towers Exchange Plaza 2nd Floor, Dalal Street Bandra-Kurla Complex,Bandra (E) Mumbai- 400001 Mumbai- 4000051 BSE Scrip Code: 544866 Symbol: MOLBIO Subject: Investor Presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026. Dear Sir/Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), please find enclosed herewith a copy of the Investor Presentation or Communication, in connection with the Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended September 30, 2026. This presentation will also be available on the Company’s website at www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. You are requested to kindly take the same on record. Thanking You. Yours Faithfully, For Molbio Diagnostics Limited Darshan Raghunath Karekar Company Secretary & Compliance Officer M. No: F13569 Date: November 05,2026 Place: Verna-Goa Innovation Led Diagnostic Products Company Investor Presentation Nov’2026 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which has been prepared by Molbio Diagnostics Ltd. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever . No offering of securities of the Company shall be made except by means of a statutory offering document containing detailed information about the Company . This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation . This Presentation may not be all inclusive and may not contain all the information that you may consider material . Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded . Stakeholders are advised to compare the data provided in the presentation with the full financial results available on the website of the Company as well as on the website of the NSE and BSE . Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward -looking statements . Such forward -looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict . These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world - wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks . The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation . The Company assumes no obligation to update any forward -looking information contained in this Presentation . Any forward -looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections . Management Commentary "H1 FY27 Total Income stood at ₹676.3 Cr, compared to ₹681.8 Cr in H1 FY26. During Q2 FY27, business performance was relatively softer as we were in the midst of rate-contract negotiations, which typically take around 1–1.5 months to complete. Consequently, the quarter does not reflect a full three months of sales. As highlighted previously, our business is not linear, and performance may vary from quarter to quarter. Historically, H1 has contributed around 35–45% of our full-year revenue. We remain committed to working towards our guidance of 25% topline growth in FY27 over FY26. Alongside our focus on business growth, we are making good progress in expanding our global presence and further strengthening our R&D portfolio. We are in advanced stages of developing new platforms to address the evolving requirements of laboratories, hospitals and doctors' clinics. We are also pleased to share that our radiology products, in addition to their applications in human healthcare, are now being deployed for veterinary use. To further strengthen our presence in veterinary segment, we are in the process of developing six new assays for veterinary applications, which will be available on our Truenat® devices. Sriram Natarajan We remain focused on strengthening our technology and product portfolio, expanding our global Executive Director, and Chief footprint and pursuing our growth objectives. We believe these initiatives will further enhance our Executive Officer (CEO) capabilities and support our long-term growth aspirations." Company & Business Overview Founders’ Journey 1990 -2004 2005 -2018 Sriram Natarajan, co-founded, Tulip Diagnostics Private Bigtec shifts its focus Joint Venture between Sriram Natarajan Limited which later towards chip -based Molbio and Bigtec exited Tulip became one of the PCR (1) research Innovations Private Diagnostics Private largest in -vitro Limited and Bigtec Limited pursuant to diagnostics reagent Private Limited sale to PerkinElmer company in India 2000 2008 2013 2018 1990 2004 2011 2017 Incorporation of Bigtec creates a Launch of the Fully - automatic Molbio Diagnostics ‘lab-on-a-chip ’ semi -automatic PCR (1) device along with its R&D model PCR (1) device "Truelab Uno’ arm Bigtec Labs ‘Truelab Uno’ approved by ICMR (2) Note: (1) Polymerase Chain Reaction (2) Indian Council of Medical Research Journey Post Commercial Launch of Truenat Platform 2019 -2022 2023 onwards • Prognosys 5 received EU MDR certification for the PRORAD radiology systems • Truenat HR-HPV Plus met IARC • Strategic validation criteria in a multicentre study investment in Investment by Investment by • Collaboration with Equine Biotech for OptraSCAN , a Motilal Oswal Temasek Holdings veterinary diagnostics development Digital Pathology Alternate Investment (Private) Ltd (3) Company • US FDA 510(k) clearance for the Advisors Pvt Ltd (2) OptraSCAN System • Launch of EDGE incubator • Listed on NSE & BSE program 2020 2023 2025 2019 2022 2024 2026 • Launch of ICMR (4) Foray in Radiology • EU IVDR Class C certification approved COVID test ; via Prognosys for Truenat ® CT/NG BioSpectrum product of Medical Systems • Prognosys 5 received US FDA the year award Private Limited 510(k) clearance for Prorad acquisition • Truenat endorsement Atlas Ultraportable and by WHO (5) for TB (1) Prorad Atlas Ultraportable Plus Note: (1) For an initial diagnosis of TB (Tuberculosis) and rifampicin resistance detection using molecular diagnostic techno logy (Source: Report titled "Molecular Diagnostics Industry Report" dated August 22, 2025 ("1Lattice Report")) (5) World Health Organisation. (2) Investment through its funds. (3) Investment through its indirect wholly owned subsidiary. (4) Indian Council of Medical Research. (5) Prognosys Medical Systems Private Limited 6 Molbio At A Glance Innovation -led diagnostics company delivering accessible, accurate a [Showing first 8,000 characters — download PDF for full document]